Etelka Ferenczi

Ms. Etelka Ferenczi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EFEtelka Ferenczi
Etelka Ferenczi
PKPéter Keglevich
Péter Keglevich
Bizhar Ahmed TayebBizhar Ahmed Tayeb
Bizhar Ahmed Tayeb
RMRenáta Minorics
Renáta Minorics
DPDávid Papp
Dávid Papp
Antal CsampaiAntal Csampai
Antal Csampai
In the frame of our diversity-oriented research on multitarget small molecule anticancer agents, utilizing convergent synthetic sequences terminated by Sonogashira coupling reactions, a preliminary selection of representative alkyne-tethered vindoline hybrids was synthesized. The novel hybrids with additional pharmacophoric fragments of well-documented anticancer agents, including FDA-approved tyrosine-kinase inhibitors (imatinib and erlotinib) or ferrocene or chalcone units, were evaluated for their antiproliferative activity on malignant cell lines MDA-MB-231 (triple negative breast cancer), A2780 (ovarian cancer), HeLa (human cervical cancer), and SH-SY5Y (neuroblastoma) as well as on human embryonal lung fibroblast cell line MRC-5, which served as a reference non-malignant cell line for the assessment of the therapeutic window of the tested hybrids. The biological assays identified a trimethoxyphenyl-containing chalcone-vindoline hybrid (36) as a promising lead compound exhibiting submicromolar activity on A2780 cells with a marked therapeutic window.

31 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
EFEtelka Ferenczi
Etelka Ferenczi
PKPéter Keglevich
Péter Keglevich
Bizhar Ahmed TayebBizhar Ahmed Tayeb
Bizhar Ahmed Tayeb
RMRenáta Minorics
Renáta Minorics
DPDávid Papp
Dávid Papp
Antal CsampaiAntal Csampai
Antal Csampai
In the frame of our diversity-oriented research on multitarget small molecule anticancer agents, utilizing convergent synthetic sequences terminated by Sonogashira coupling reactions, a preliminary selection of representative alkyne-tethered vindoline hybrids was synthesized. The novel hybrids with additional pharmacophoric fragments of well-documented anticancer agents, including FDA-approved tyrosine-kinase inhibitors (imatinib and erlotinib) or ferrocene or chalcone units, were evaluated for their antiproliferative activity on malignant cell lines MDA-MB-231 (triple negative breast cancer), A2780 (ovarian cancer), HeLa (human cervical cancer) and SH-SY5Y (neuroblastoma) as well as human embryonal lung fibroblast MRC-5 served as reference non-malignant cell line for the assessment of the therapeutic window of the tested hybrids. The biological assays identified a trimethoxyphenyl-containing chalcone-vindoline hybrid (36) as a promising lead compound exhibiting submicromolar activity on A2780 cells with a marked therapeutic window. These results suggest that ovarian cancer might be considered as a prioritized target of treatment with 36.

2 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
EFEtelka Ferenczi
Etelka Ferenczi
DMDóra K. Menyhárd
Dóra K. Menyhárd
AKAdriána Kovács
Adriána Kovács
AGAgnes Gomory
Agnes Gomory
László DrahosLászló Drahos
László Drahos
Antal CsampaiAntal Csampai
Antal Csampai
In the frame of our ongoing research on multitarget alkaloid-derived anticancer agents, relying on a modular synthetic strategy terminated by well-established sequential Sonogashira and CuAAC protocols, we synthesized a systematic selection of chalcone-vindoline hybrids incorporating 1,4-disubstituted 1,2,3-triazole as a linker. The use of the same synthetic approach led to the construction of a zidovudine-derived vindoline hybrid, which served as a negative control highlighting the essential contribution of the chalcone moiety to the antiproliferative activity. Two analogous aryl-substituted chalcone hybrids 14a,b were also prepared to assess the contribution of the vindoline fragment to the desired effect. The targeted hybrids and the references were evaluated for their antiproliferative activity against a panel of human adherent gynecological cancer cell lines (HeLa, SiHa, MCF-7, MDA-MB-231 and A2780) as well as on non-malignant fibroblasts (NIH/3T3). Vindoline hybrids 10a and 10i comprising 3,4,5- and 1,4,6-trimethoxyphenyl-substituted chalcone fragments, respectively, displayed substantial activity, featuring IC50 values lower than 0.4 µM on all the investigated cancer cell lines. On the other hand, hybrids 10c–e containing monomethoxy-substituted chalcones, also featuring submicromolar IC50 values on malignant cells, showed moderately lower activities against non-malignant fibroblasts (NIH/3T3), indicating a certain degree of cancer selectivity. The related ferrocene-derived hybrid (10i) and vindoline-free chalcones 14a,b were identified as antiproliferative agents with significantly decreased efficiency, while the ferrocene hybrid comprising an alternative enone sequence in the chalcone residue (11) as well as the zidovudine-derived vindoline hybrid 12 were inactive. Modeling results indicate that the vindoline hybrids bind to the inter-dimer vinca crevice of tubulin oligomers and confirm that the two segments exert a mutually stabilizing effect on the binding of the other, providing a framework for future structure optimization.

8 November 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
EFEtelka Ferenczi
Etelka Ferenczi
DMDóra K. Menyhárd
Dóra K. Menyhárd
AKAdriána Kovács
Adriána Kovács
AGAgnes Gomory
Agnes Gomory
László DrahosLászló Drahos
László Drahos
Antal CsampaiAntal Csampai
Antal Csampai
Background/Objectives: Cancer is one of the leading causes of mortality worldwide. However, due to limitations in clinical treatment of malignancies, there is a continuous need for the development of more potent novel drugs with enhanced activity and selectivity towards tumours. Methods: In this context, we synthesised a focused library of chalcone–vindoline hybrids incorporating a 1,4-disubstituted 1,2,3-triazole linker using a modular strategy combining sequential Sonogashira coupling and CuAAC reactions. The same synthetic route afforded a zidovudine-derived vindoline hybrid, which served as a negative control to underscore the pivotal role of the chalcone moiety in mediating antiproliferative activity. To elucidate the contribution of the vindoline scaffold, two corresponding aryl-substituted chalcone analogues were also prepared. The synthesised hybrids and the reference compounds were evaluated against a panel of human adherent cancer cell lines (HeLa, SiHa, MCF-7, MDA-MB-231 and A2780) and non-malignant NIH/3T3 fibroblasts. Results: Vindoline hybrids incorporating trimethoxyphenyl chalcone moieties exhibited outstanding potency on all the cancer cell lines tested. By contrast, hybrids containing monomethoxy-substituted chalcone moieties with moderately reduced activity against malignant cells displayed a certain degree of cancer selectivity. A ferrocene-containing hybrid and the vindoline-free chalcones exhibited markedly lower antiproliferative activity, whereas another ferrocene hybrid featuring an alternative enone configuration and the zidovudine-derived vindoline hybrid were inactive. Molecular modelling results indicate that the vindoline hybrids might bind to the inter-dimer vinca crevice of tubulin oligomers and that the two segments exert a mutually stabilising effect on the binding of the other. Conclusion: Collectively, these findings provide a framework for future rational optimisation of this promising class of anticancer agents.